Skip to main content

Advertisement

Remise en cause de la réalité d’une augmentation de la mortalité cardiovasculaire sous traitement par privation androgénique pour cancer de la prostate ?

Questioning the reality of an increase in cardiovascular mortality with androgen deprivation therapy for prostate cancer?

Références

  1. 1.

    Buvat J, Maggi M, Gooren L, et al (2010) Endocrine aspects of male sexual dysfunctions. J Sex Med 7:1627–1656

  2. 2.

    Corona G, Rastrelli G, Monami M, et al (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165:1–18

  3. 3.

    Punnen S, Cooperberg MR, Sadetsky N, Carroll PR (2001) Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 29:3510–3516

  4. 4.

    Efstathiou JA, Bae K, Shipley WU, et al (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54:816–823

  5. 5.

    Efstathiou JA, Bae K, Shipley WU, et al (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27:92–99

  6. 6.

    Von Eckardstein A, Wu FCW (2004) Testosterone and cardiovascular diseases. In Nieschlag E, Behre HM (eds) Testosterone Action, Deficiency, Substitution. Cambridge University Press, Cambridge, pp 297–332

  7. 7.

    McGrath KC, McRobb LS, Heather AK (2008) Androgen therapy and atherosclerotic cardiovascular disease. Vasc Health Risk Manag 4:11–21

Download references

Author information

Correspondence to J. Buvat.

Rights and permissions

Reprints and Permissions

About this article